{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:43:32Z","timestamp":1790361812971,"version":"4.1.0"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.1093\/jac\/dky265","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T03:06:45Z","timestamp":1529291205000},"page":"2907-2915","source":"Crossref","is-referenced-by-count":25,"title":["The 2018 Garrod Lecture: Preparing for the Black Swans of resistance"],"prefix":"10.1093","volume":"73","author":[{"given":"David M","family":"Livermore","sequence":"first","affiliation":[{"name":"Norwich Medical School, University of East Anglia, Norwich, Norfolk, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,25]]},"reference":[{"key":"key\n\t\t\t\t20181023055608946_dky265-B1","author":"Anon"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.medmal.2011.07.005","article-title":"French results of the ARESC study: clinical aspects and epidemiology of antimicrobial resistance in female patients with cystitis. Implications for empiric therapy","volume":"42","author":"Neuzillet","year":"2012","journal-title":"Med Mal Infect"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B3","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1128\/CMR.00002-15","article-title":"Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections","volume":"28","author":"Crump","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B4","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S1473-3099(17)30310-9","article-title":"Sexually-transmitted infections: challenges ahead","volume":"17","author":"Unemo","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/ijmr.IJMR_177_16","article-title":"Extensively drug-resistant tuberculosis in India: current evidence on diagnosis and management","volume":"145","author":"Prasad","year":"2017","journal-title":"Indian J Med Res"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1465-0691.2004.1006.x","article-title":"Antibacterial drug discovery: is it all downhill from here?","volume":"10","author":"Projan","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd2201","article-title":"Drugs for bad bugs: confronting the challenges of antibacterial discovery","volume":"6","author":"Payne","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CMR.00030-10","article-title":"Challenges of antibacterial discovery","volume":"24","author":"Silver","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B9","first-page":"420","article-title":"The United States Food and Drug Administration and the end of antibiotics","volume":"34","author":"Shlaes","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B10","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1093\/jac\/dkr259","article-title":"Regulatory opportunities to encourage technology solutions to antibacterial drug resistance","volume":"66","author":"Finch","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B11","volume-title":"New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options","author":"Sharma","year":"2011"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijantimicag.2014.01.011","article-title":"Of stewardship, motherhood and apple pie","volume":"43","author":"Livermore","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3947\/ic.2013.45.1.1","article-title":"Revolutionising bacteriology to improve treatment outcomes and antibiotic stewardship","volume":"45","author":"Livermore","year":"2013","journal-title":"Infect Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/14787210.2016.1233814","article-title":"Implementation of rapid diagnostics with antimicrobial stewardship","volume":"14","author":"Minejima","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B15","author":"O\u2019Neill"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B16","author":"WHO"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B17","author":"The Pew Charitable Trusts"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B18","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/cid\/ciw593","article-title":"Economic incentives for antibacterial drug development: literature review and considerations from the Transatlantic Task Force on Antimicrobial Resistance","volume":"63","author":"Sciarretta","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1377\/hlthaff.2014.1003","article-title":"Repairing the broken market for antibiotic innovation","volume":"34","author":"Outterson","year":"2015","journal-title":"Health Aff (Millwood)"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B20","article-title":"A risk assessment of antibiotic pan-drug-resistance in the UK: Bayesian analysis of an expert elicitation study","volume":"6","author":"Carter","year":"2017","journal-title":"Antibiotics (Basel)"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B21","volume-title":"When Genius Failed","author":"Lowenstein","year":"2000"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B22","volume-title":"The Black Swan","author":"Taleb","year":"2007"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B23","author":"Anon"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1469-0691.2006.01492.x","article-title":"The emergence of antibiotic resistance by mutation","volume":"13","author":"Woodford","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B25","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF02013107","article-title":"Clinical significance of \u03b2-lactamase induction and stable derepression in Gram-negative rods","volume":"6","author":"Livermore","year":"1987","journal-title":"Eur J Clin Microbiol"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B26","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1128\/AAC.45.9.2628-2630.2001","article-title":"Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp","volume":"45","author":"Kaye","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B27","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1128\/AAC.31.12.1892","article-title":"Emergence of resistance to imipenem in Pseudomonas aeruginosa","volume":"31","author":"Lynch","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1128\/AAC.03774-14","article-title":"Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections","volume":"59","author":"O\u2019Dwyer","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B29","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1128\/AAC.00678-15","article-title":"In vitro selection of ceftazidime\/avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase","volume":"59","author":"Livermore","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B30","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/ciw636","article-title":"Clinical outcomes, drug toxicity, and emergence of ceftazidime\/avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections","volume":"63","author":"Shields","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B31","doi-asserted-by":"crossref","first-page":"e01183-17","DOI":"10.1128\/AAC.01183-17","article-title":"Emergence of ceftolozane\/tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation","volume":"61","author":"MacVane","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B32","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B33","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1128\/AAC.00356-10","article-title":"Origin and molecular evolution of the determinant of methicillin resistance in staphylococci","volume":"54","author":"Tsubakishita","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1469-0691.2008.02679.x","article-title":"Antibiotic resistance genes from the environment: a perspective through newly identified antibiotic resistance mechanisms in the clinical setting","volume":"15","author":"Cant\u00f3n","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B35","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/jac\/dkx225","article-title":"MCR-2-mediated plasmid-borne polymyxin resistance most likely originates from Moraxella pluranimalium","volume":"72","author":"Poirel","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B36","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/jac\/5.4.349","article-title":"Plasmid-mediated \u03b2-lactamases of Gram-negative bacteria: properties and distribution","volume":"5","author":"Matthew","year":"1979","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jac\/18.Supplement_C.25","article-title":"Molecular biology of transposable elements","volume":"18","author":"Schmitt","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B38","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.MDNA3-0060-2014","article-title":"The Tn3-family of replicative transposons","volume":"3","author":"Nicolas","year":"2015","journal-title":"Microbiol Spectr"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijantimicag.2011.12.012","article-title":"Fourteen years in resistance","volume":"39","author":"Livermore","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B40","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/jac\/dkt212","article-title":"Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream Enterobacteriaceae from the UK: links to prescribing change?","volume":"68","author":"Livermore","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/jac\/30.4.429","article-title":"Survey of the prevalence of \u03b2-lactamases amongst 1000 Gram-negative bacilli isolated consecutively at the Royal London Hospital","volume":"30","author":"Liu","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/jac\/dkl483","article-title":"CTX-M: changing the face of ESBLs in Europe","volume":"59","author":"Livermore","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1128\/CMR.00125-13","article-title":"Escherichia coli ST131, an intriguing clonal group","volume":"27","author":"Nicolas-Chanoine","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B44","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1099\/jmm.0.000179","article-title":"Characterization of the extra-intestinal pathogenic Escherichia coli ST131 clone among isolates recovered from urinary and bloodstream infections in the United Kingdom","volume":"64","author":"Ciesielczuk","year":"2015","journal-title":"J Med Microbiol"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B45","volume-title":"The Sleepwalkers: How Europe Went to War in 1914","author":"Clark","year":"2013"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1126\/science.1120800","article-title":"Sampling the antibiotic resistome","volume":"311","author":"D'Costa","year":"2006","journal-title":"Science"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B47","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/AAC.05441-11","article-title":"Inactivation of the lipopeptide antibiotic daptomycin by hydrolytic mechanisms","volume":"56","author":"D'Costa","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B48","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1128\/MMBR.57.1.138-163.1993","article-title":"Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes","volume":"57","author":"Shaw","year":"1993","journal-title":"Microbiol Rev"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B49","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.idc.2016.02.011","article-title":"Aminoglycoside resistance: the emergence of acquired 16S ribosomal RNA methyltransferases","volume":"30","author":"Doi","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B50","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1128\/AAC.44.3.705-709.2000","article-title":"The biopesticide Paenibacillus popilliae has a vancomycin resistance gene cluster homologous to the enterococcal VanA vancomycin resistance gene cluster","volume":"44","author":"Patel","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B51","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1128\/AAC.49.10.4227-4233.2005","article-title":"Glycopeptide resistance vanA operons in Paenibacillus strains isolated from soil","volume":"49","author":"Guardabassi","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B52","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s000180050023","article-title":"Genetic basis of methicillin resistance in Staphylococcus aureus","volume":"56","author":"Berger-B\u00e4chi","year":"1999","journal-title":"Cell Mol Life Sci"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B53","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1128\/AAC.16.5.533","article-title":"Affinities of penicillins and cephalosporins for the penicillin-binding proteins of Escherichia coli K-12 and their antibacterial activity","volume":"16","author":"Curtis","year":"1979","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B54","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7164\/antibiotics.37.394","article-title":"Studies on the mechanism of action of imipenem (N-formimidoylthienamycin) in vitro: binding to the penicillin-binding proteins (PBPs) in Escherichia coli and Pseudomonas aeruginosa, and inhibition of enzyme activities due to the PBPs in E. coli","volume":"37","author":"Hashizume","year":"1984","journal-title":"J Antibiot"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B55","volume-title":"The Loss of the SS Titanic: Its Story and Lessons","author":"Beesley","year":"1912"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B56","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1128\/AAC.33.8.1131","article-title":"Extended-spectrum \u03b2-lactamases","volume":"33","author":"Philippon","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1128\/AAC.35.1.147","article-title":"Transferable imipenem resistance in Pseudomonas aeruginosa","volume":"35","author":"Watanabe","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B58","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1099\/jmm.0.052555-0","article-title":"Global spread of antibiotic resistance: the example of New Delhi metallo-\u03b2-lactamase (NDM)-mediated carbapenem resistance","volume":"62","author":"Johnson","year":"2013","journal-title":"J Med Microbiol"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B59","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.00756-10","article-title":"Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae","volume":"55","author":"Livermore","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B60","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/jac\/dkw593","article-title":"In vitro activity of cefepime\/zidebactam (WCK 5222) against Gram-negative bacteria","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B61","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1128\/AAC.02184-15","article-title":"Interactions of OP0595, a novel triple-action diazabicyclooctane, with \u03b2-lactams against OP0595-resistant Enterobacteriaceae mutants","volume":"60","author":"Livermore","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B62","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1093\/jac\/dkv166","article-title":"OP0595, a new diazabicyclooctane: mode of action as a serine \u03b2-lactamase inhibitor, antibiotic and \u03b2-lactam \u2032enhancer\u2032","volume":"70","author":"Morinaka","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B63","author":"Mushtaq"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B64","author":"WHO"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B65","author":"Mushtaq"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B66","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/AAC.01695-15","article-title":"In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains","volume":"60","author":"Kohira","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B67","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bmcl.2018.01.006","article-title":"Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae \u2013 identification of LYS228","volume":"28","author":"Reck","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B68","first-page":"149","volume-title":"Topics in Medicinal Chemistry","author":"Shlaes","year":"2018"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B70","first-page":"1396","article-title":"In vitro activity of ceftazidime\/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections","volume":"72","author":"Stone","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B71","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime\/avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1469-0691.2007.01858.x","article-title":"Orthodox and unorthodox clavulanate combinations against extended-spectrum \u03b2-lactamase producers","volume":"14","author":"Livermore","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B73","doi-asserted-by":"crossref","first-page":"e02409-16.","DOI":"10.1128\/AAC.02409-16","article-title":"Antimicrobial activity of high-proportion cefepime\/tazobactam (WCK 4282) against a large number of Gram-negative isolates collected worldwide in 2014","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B74","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/jac\/dkx360","article-title":"Potential of high-dose cefepime\/tazobactam against multiresistant Gram-negative pathogens","volume":"73","author":"Livermore","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B75","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: a systematic review and meta-analysis","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B76","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/655131","article-title":"Meta-analysis of a possible signal of increased mortality associated with cefepime use","volume":"51","author":"Kim","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B77","doi-asserted-by":"crossref","first-page":"e00528-17","DOI":"10.1128\/mBio.00528-17","article-title":"Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at Ambler position Asp179, and resistance to ceftazidime\/avibactam: unique antibiotic-resistant phenotypes emerge from \u03b2-lactamase protein engineering","volume":"8","author":"Barnes","year":"2017","journal-title":"MBio"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B78","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkx438","article-title":"Activity of ceftazidime\/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015\u201316","volume":"73","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B79","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1128\/AAC.00264-16","article-title":"Successful treatment of bloodstream infection due to metallo-\u03b2-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient","volume":"60","author":"Mojica","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B80","doi-asserted-by":"crossref","first-page":"e01008-17","DOI":"10.1128\/AAC.01008-17","article-title":"Ceftazidime\/avibactam and aztreonam, an interesting strategy to overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa","volume":"61","author":"Davido","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B81","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1128\/AAC.42.5.1303","article-title":"Historical yearly usage of vancomycin","volume":"42","author":"Kirst","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B82","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1469-0691.2004.01043.x","article-title":"Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic","volume":"11","author":"Michalopoulos","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B83","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/BF01691374","article-title":"Haemophilus influenzae: then and now","volume":"14","author":"Jordens","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B84","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1016\/j.vaccine.2017.09.053","article-title":"Enhancing the role of vaccines in combatting antimicrobial resistance","volume":"35","author":"Clift","year":"2017","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B85","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1473-3099(17)30108-1","article-title":"Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial","volume":"17","author":"Huttner","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20181023055608946_dky265-B86","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1473-3099(15)00466-1","article-title":"Alternatives to antibiotics\u2014a pipeline portfolio review","volume":"16","author":"Czaplewski","year":"2016","journal-title":"Lancet Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/11\/2907\/26144627\/dky265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:41:55Z","timestamp":1751690515000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/11\/2907\/5059523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,25]]},"references-count":86,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,7,25]]},"published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky265","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,7,25]]}}}